Market Place
Sourcing Support
Nabriva Tx Expands XENLETA Presence with Excl. Agreement with Er-Kim Pharma
18 Jul 2022 //
GLOBENEWSWIRE
Nabriva Begins Enrollment in PI Trial of XENLETA for Cystic Fibrosis
11 Apr 2022 //
GLOBENEWSWIRE
Nabriva Announces Availability of XENLETA in a 10-Count Oral Pack
11 Nov 2021 //
GLOBENEWSWIRE
Nabriva Publishes Data DemonstratingAnti-Inflammatory Properties of XENLETA®
04 Oct 2021 //
GLOBENEWSWIRE
Nabriva Publishes Data DemonstratingAnti-Inflammatory Properties of XENLETA®
04 Oct 2021 //
GLOBENEWSWIRE
Nabriva Therapeutics to Present Data at IDWeek 2021
24 Sep 2021 //
GLOBENEWSWIRE
Nabriva shares rise after Xenleta approval in Taiwan
08 Sep 2021 //
SEEKING ALPHA
NABRIVA Receives European Approval for XENLETA® (lefamulin)
28 Jul 2020 //
GLOBENEWSWIRE
Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study
23 Jul 2020 //
GLOBENEWSWIRE
XENLETA® (lefamulin) Receives Health Canada Approva
16 Jul 2020 //
GLOBENEWSWIRE
WEP Clinical Partners With Nabriva for the Named Patient Supply of XENLETA®
06 Jul 2020 //
BUSINESSWIRE
New vaccine for Ebola among CHMP recommendations
01 Jun 2020 //
PHARMATIMES
XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response
05 May 2020 //
GLOBENEWSWIRE
Centers for Medicare & Medicaid Services Issues Product-Specific J-Code XENLETA
09 Apr 2020 //
BUSINESSINSIDER
Nabriva to Present Data at the CHEST Annual Meeting
15 Oct 2019 //
BIOSPACE
FDA approves new antibiotic to treat community-acquired bacterial pneumonia
20 Aug 2019 //
BIOSPECTRUMASIA
Nabriva scores its first FDA nod with novel antibiotic Xenleta
20 Aug 2019 //
FIERCE PHARMA
FDA approves Nabriva`s antibiotic for pneumonia
19 Aug 2019 //
ECONOMICTIMES
Roivant brings Pfizer vets Azoulay, Gulfo into its C-suite
19 May 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.